{
    "id": 96,
    "premise": "none",
    "hypothesis": "Patient could receive treatment with vemurafenib for V600E mutation",
    "label": "entailment",
    "explanation": "Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Patient could receive treatment with vemurafenib for V600E mutation",
        "history explanation": [
            "0 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "1 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "2 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "3 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "4 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "5 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "6 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "7 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "8 iteration: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib.\nIf a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation.",
            "9 iteration: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib.\nIf a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation.",
            "10 iteration: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib.\nIf a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.713254690170288, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common_BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  SelectivelyBinds :: \"event \u21d2 bool\"\\n  ATPbindingSiteOf :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitsActivity :: \"event \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x. Patient x \u2227 Common_BRAF_V600E_Mutation x\"\\n\\n(* Explanation 2: vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Vemurafenib x \u27f6 LowMolecularWeight x \u2227 OrallyAvailable x \u2227 Inhibitor x \u2227 (\u2200e. SelectivelyBinds e \u2227 ATPbindingSiteOf e BRAF_V600E_Kinase \u2227 InhibitsActivity e)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 For e z\"\\nproof -\\n  (* From the premise, we know that the patient has common BRAF V600E mutation and is receiving treatment with vemurafenib for V600E mutation. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z\" <ATP>\\n  (* There is a logical relation Implies(A, D), Implies(Patient has common BRAF V600E mutation, vemurafenib inhibits the activity of BRAF V600E kinase). *)\\n  (* Since the patient has common BRAF V600E mutation, we can infer that vemurafenib inhibits the activity of BRAF V600E kinase. *)\\n  then have \"Patient x \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 For e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: vemurafenib selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: vemurafenib inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patient has common BRAF V600E mutation, vemurafenib is a low-molecular-weight, orally available inhibitor)\\n--------\\nImplies(B, C)\\nImplies(vemurafenib is a low-molecular-weight, orally available inhibitor, vemurafenib selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(vemurafenib selectively binds to the ATPbinding site of BRAF V600E kinase, vemurafenib inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(B))\\nImplies(Not(vemurafenib inhibits the activity of BRAF V600E kinase), Not(vemurafenib is a low-molecular-weight, orally available inhibitor))\\n--------\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, vemurafenib selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(vemurafenib inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(vemurafenib selectively binds to the ATPbinding site of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(B, D)\\nImplies(vemurafenib is a low-molecular-weight, orally available inhibitor, vemurafenib inhibits the activity of BRAF V600E kinase)\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, vemurafenib inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.032752513885498, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common_BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  ATPbindingSite :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  InhibitsActivity :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x. Patient x \u2227 Common_BRAF_V600E_Mutation x\"\\n\\n(* Explanation 2: vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. Vemurafenib x \u2227 LowMolecularWeight x \u2227 OrallyAvailable x \u2227 Inhibitor x \u2227 (\u2203z. ATPbindingSite z \u2227 BRAF_V600E_Kinase z \u2227 BindsTo x z) \u2227 InhibitsActivity x\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With x z\"\\nproof -\\n  (* From the premise, we know that the patient has a common BRAF V600E mutation and is receiving treatment with vemurafenib for V600E mutation. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z \u2227 V600E_Mutation z\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase) *)\\n  (* We can infer that the patient selectively binds to the ATPbinding site of BRAF V600E kinase. *)\\n  then have \"Patient x \u2227 (\u2203z. ATPbindingSite z \u2227 BRAF_V600E_Kinase z \u2227 BindsTo z x)\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase) *)\\n  (* Therefore, we can conclude that the patient inhibits the activity of BRAF V600E kinase. *)\\n  then have \"Patient x \u2227 InhibitsActivity x\" <ATP>\\n  (* We can now construct the final conclusion by combining the known information with the derived implications. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.598195314407349, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Binds :: \"entity \u21d2 bool\"\\n  Selectively :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  ATPbinding_site_of_BRAF_V600E_kinase :: \"entity\"\\n  Inhibits :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Common y \u2227 BRAF_V600E_Mutation y \u2227 Has x y\"\\n\\n(* Explanation 2: vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w v. Vemurafenib x \u2227 LowMolecularWeight y \u2227 OrallyAvailable z \u2227 Inhibitor w \u2227 Binds v \u2227 Selectively v \u2227 To v ATPbinding_site_of_BRAF_V600E_kinase \u2227 Inhibits w v\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With e z\"\\nproof -\\n  (* From the premise, we know that the patient has a V600E mutation and is receiving treatment with vemurafenib. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z \u2227 V600E_Mutation z\" <ATP>\\n  (* We have an explanatory sentence that vemurafenib is an inhibitor that binds selectively to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\n  (* There is a logical relation Implies(C, D), Implies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase) *)\\n  (* Since the patient has a V600E mutation, which is related to the BRAF V600E kinase, we can infer that the patient\\'s mutation is inhibited. *)\\n  then have \"Patient x \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Inhibits w v\" for w v <ATP>\\n  (* We can introduce the concept of receiving treatment and the agent and patient involved in the treatment. *)\\n  then have \"\u2203e. Patient x \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Inhibits w v \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With e z\" for y <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.384788274765015, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  ATPbindingSite :: \"entity \u21d2 entity \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  InhibitsActivity :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Common y \u2227 BRAF_V600E_Mutation y \u2227 Has x y\"\\n\\n(* Explanation 2: vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w. Vemurafenib x \u2227 LowMolecularWeight y \u2227 OrallyAvailable z \u2227 Inhibitor w \u2227 ATPbindingSite w BRAF_V600E_Kinase \u2227 BindsTo w y \u2227 InhibitsActivity w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With x z\"\\nproof -\\n  (* From the premise, we know that the patient has a common BRAF V600E mutation and is receiving treatment with vemurafenib. *)\\n  from asm obtain x y z where \"Patient x \u2227 Common y \u2227 BRAF_V600E_Mutation y \u2227 Has x y \u2227 Vemurafenib z \u2227 V600E_Mutation z\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase) *)\\n  (* A is from explanatory sentence 1, C is from explanatory sentence 2. *)\\n  (* We can infer that the patient\\'s mutation leads to the inhibition of the activity of BRAF V600E kinase. *)\\n  then have \"InhibitsActivity BRAF_V600E_Kinase\" <ATP>\\n  (* We can construct the conclusion based on the known information. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 8.756675958633423, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 bool\"\\n  Selectively :: \"entity \u21d2 bool\"\\n  ATPbindingSite :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  Inhibits :: \"entity \u21d2 bool\"\\n  Activity :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Common y \u2227 BRAF_V600E_Mutation y \u2227 Has x y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w. Vemurafenib x \u2227 Inhibitor y \u2227 LowMolecularWeight y \u2227 OrallyAvailable y \u2227 BindsTo z \u2227 Selectively z \u2227 ATPbindingSite z \u2227 BRAF_V600E_Kinase w \u2227 Inhibits w \u2227 Activity w\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Common y \u2227 BRAF_V600E_Mutation y\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With x z\"\\nproof -\\n  (* From the premise, we know that the patient has a common BRAF V600E mutation. *)\\n  from asm obtain a b where \"Patient x \u2227 Common b \u2227 BRAF_V600E_Mutation b \u2227 Has x b\" by auto\\n  (* There is a logical relation Implies(A, C), Implies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase) *)\\n  (* We can infer that the patient selectively binds to the ATPbinding site of BRAF V600E kinase. *)\\n  then have \"Patient x \u2227 Selectively c \u2227 ATPbindingSite c \u2227 BRAF_V600E_Kinase d\" for c d by auto\\n  (* There is a logical relation Implies(C, D), Implies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase) *)\\n  (* Therefore, we can conclude that the patient inhibits the activity of BRAF V600E kinase. *)\\n  then have \"Patient x \u2227 Inhibits d \u2227 Activity d\" for d by auto\\n  (* From the explanation 2, we know that vemurafenib is a low-molecular-weight, orally available inhibitor. *)\\n  then obtain e where \"Vemurafenib e \u2227 Inhibitor e \u2227 LowMolecularWeight e \u2227 OrallyAvailable e\" by auto\\n  (* We can combine the information to form the desired conclusion. *)\\n  then show ?thesis by auto\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.76076340675354, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 bool\"\\n  Selectively :: \"entity \u21d2 bool\"\\n  ATPbindingSite :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  InhibitsActivity :: \"entity \u21d2 bool\"\\n  Of :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Common y \u2227 BRAF_V600E_Mutation y \u2227 Has x y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w. Vemurafenib x \u2227 Inhibitor y \u2227 LowMolecularWeight y \u2227 OrallyAvailable y \u2227 BindsTo z \u2227 Selectively z \u2227 ATPbindingSite z \u2227 BRAF_V600E_Kinase w \u2227 InhibitsActivity w \u2227 Of z w\"\\n\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With e z\"\\nproof -\\n  (* From the premise, we can get known information about the patient, treatment, and vemurafenib. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase) *)\\n  (* A is from explanatory sentence 1, C is from explanatory sentence 2. *)\\n  (* We already have Patient has common BRAF V600E mutation, so we can infer selectively binds to the ATPbinding site of BRAF V600E kinase. *)\\n  then have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 9.635148048400879, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: ??\\'a\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF :: \"entity \u21d2 bool\"\\n  V600E :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Binds :: \"entity \u21d2 bool\"\\n  Selectively :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  ATPBindingSite :: \"entity \u21d2 bool\"\\n  Kinase :: \"entity \u21d2 bool\"\\n  Inhibits :: \"entity \u21d2 bool\"\\n  Activity :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Common y \u2227 BRAF y \u2227 V600E y \u2227 Mutation y \u2227 Has x y\"\\n\\n(* Explanation 2: vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w. Vemurafenib x \u2227 Inhibitor y \u2227 LowMolecularWeight y \u2227 OrallyAvailable y \u2227 Binds z \u2227 Selectively z \u2227 To z w \u2227 ATPBindingSite w \u2227 BRAF w \u2227 V600E w \u2227 Kinase w \u2227 Inhibits w \u2227 Activity w\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E z \u2227 Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E z \u2227 Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With e z\"\\nproof -\\n  (* From the premise, we know that the patient has a mutation and is receiving treatment with vemurafenib for V600E mutation. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z \u2227 V600E z \u2227 Mutation z\" <ATP>\\n  (* There is an explanatory sentence stating that the patient has a common BRAF V600E mutation. *)\\n  (* There is a logical relation Implies(A, C), Implies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase) *)\\n  (* Since the patient has a common BRAF V600E mutation, it implies that vemurafenib selectively binds to the ATPbinding site of BRAF V600E kinase. *)\\n  then have \"Patient x \u2227 Vemurafenib z \u2227 V600E z \u2227 Mutation z \u2227 Binds z \u2227 Selectively z \u2227 To z w \u2227 ATPBindingSite w \u2227 BRAF w \u2227 V600E w \u2227 Kinase w \u2227 Inhibits w \u2227 Activity w\" <ATP>\\n  (* We can infer that the patient is receiving treatment, and the agent is the patient, the patient is the recipient, and the treatment is with vemurafenib for V600E mutation. *)\\n  then have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E z \u2227 Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': '(* From the premise, we know that the patient has a common BRAF V600E mutation and is receiving treatment with vemurafenib. *)\\nfrom asm obtain a b where \"Patient x \u2227 Common b \u2227 BRAF_V600E_Mutation b \u2227 Has x b \u2227 Vemurafenib z \u2227 V600E_Mutation z\" sledgehammer', 'solving time': 89.25558853149414, 'proof tactics': [], 'code': 'theory clinical_96_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  BindsTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  ATPbindingSite :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  Inhibits :: \"entity \u21d2 entity \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Common y \u2227 BRAF_V600E_Mutation y \u2227 Has x y\"\\n\\n(* Explanation 2: vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w. Vemurafenib x \u2227 Inhibitor y \u2227 LowMolecularWeight y \u2227 OrallyAvailable y \u2227 BindsTo x z \u2227 ATPbindingSite z \u2227 BRAF_V600E_Kinase z \u2227 Inhibits x z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With x z\"\\nproof -\\n  (* From the premise, we know that the patient has a common BRAF V600E mutation and is receiving treatment with vemurafenib. *)\\n  from asm obtain a b where \"Patient x \u2227 Common b \u2227 BRAF_V600E_Mutation b \u2227 Has x b \u2227 Vemurafenib z \u2227 V600E_Mutation z\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase) *)\\n  (* We can infer that the patient\\'s mutation leads to the binding to the ATPbinding site of BRAF V600E kinase. *)\\n  then obtain c where \"BindsTo z c \u2227 ATPbindingSite c \u2227 BRAF_V600E_Kinase c\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase) *)\\n  (* Therefore, we can conclude that the treatment with vemurafenib inhibits the activity of BRAF V600E kinase. *)\\n  then obtain e where \"Inhibits z e\" <ATP>\\n  (* We have all the necessary components to show that the patient could receive treatment with vemurafenib for V600E mutation. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has common BRAF V600E mutation\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor\\nC: selectively binds to the ATPbinding site of BRAF V600E kinase\\nD: inhibits the activity of BRAF V600E kinase\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has common BRAF V600E mutation, selectively binds to the ATPbinding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(selectively binds to the ATPbinding site of BRAF V600E kinase, inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(inhibits the activity of BRAF V600E kinase), Not(Patient has common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has common BRAF V600E mutation, inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_96_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common_BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 bool\"\\n  V600E_Mutation :: \"entity \u21d2 bool\"\\n  Receiving :: \"entity \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Patient x \u2227 Common_BRAF_V600E_Mutation y \u2227 Has z \u2227 V600E_Mutation z \u27f6 (Receiving e \u2227 Agent e x \u2227 Patient e z \u2227 With z x)\"\\n\\n(* Explanation 2: If a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Patient x \u2227 Receiving y \u2227 Treatment z \u2227 Vemurafenib z \u27f6 (Has e \u2227 Agent e x \u2227 Patient e z \u2227 Common_BRAF_V600E_Mutation z)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z \u2227 Receiving e \u2227 Agent e x \u2227 Patient e z \u2227 With z x\"\\nproof -\\n  (* From the premise, we know that the patient has a V600E mutation and is receiving treatment with vemurafenib. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600E_Mutation z\" <ATP>\\n  (* We can use the logical relation Implies(B, A) to infer that if the patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation. *)\\n  (* This relation is derived from Explanation 2. *)\\n  (* Therefore, we can conclude that the patient has a common BRAF V600E mutation. *)\\n  from explanation_2 and asm have \"Patient x \u2227 Receiving z \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z\" <ATP>\\n  (* Now, we have the necessary information to show that the patient is receiving treatment with vemurafenib for the V600E mutation. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a common BRAF V600E mutation\\nB: patient is receiving treatment with vemurafenib\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a common BRAF V600E mutation, patient is receiving treatment with vemurafenib)\\n--------\\nImplies(B, A)\\nImplies(patient is receiving treatment with vemurafenib, patient has a common BRAF V600E mutation)\\n--------\\n\\nDerived Implications:\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_96_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common_BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 bool\"\\n  Agent :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Patient x \u2227 Common_BRAF_V600E_Mutation y \u2227 Has z \u2227 Agent z x y \u27f6 (Receive e \u2227 Agent e x \u2227 Patient e \u2227 Treatment e \u2227 With x Vemurafenib)\"\\n\\n(* Explanation 2: If a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x y \u2227 Patient y \u2227 With x z \u27f6 (Has z \u2227 Agent z x \u2227 Patient z \u2227 Common_BRAF_V600E_Mutation z)\"\\n\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z \u2227 Receive e \u2227 Agent e x y \u2227 Patient y \u2227 With x z\"\\nproof -\\n  (* From the premise, we have the information about the patient, treatment, vemurafenib, and common BRAF V600E mutation. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z\" <ATP>\\n  (* There are two explanatory sentences relevant to the hypothesis. *)\\n  (* Explanation 1: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib. *)\\n  (* Explanation 2: If a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation. *)\\n  (* Using the logical relations Implies(A, B) and Implies(B, A), we can infer the hypothesis. *)\\n  (* Since we have the common BRAF V600E mutation and vemurafenib treatment, we can conclude the rest of the information. *)\\n  then have \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z \u2227 Receive e \u2227 Agent e x y \u2227 Patient y \u2227 With x z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a common BRAF V600E mutation\\nB: patient is receiving treatment with vemurafenib\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a common BRAF V600E mutation, patient is receiving treatment with vemurafenib)\\n--------\\nImplies(B, A)\\nImplies(patient is receiving treatment with vemurafenib, patient has a common BRAF V600E mutation)\\n--------\\n\\nDerived Implications:\\n'}",
            "10 iteration: {'syntactic validity': True, 'error code': '(* Using Explanation 2: If a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation. *)\\n(* We can infer that the patient has a common BRAF V600E mutation and has a mutation related to the treatment. *)\\nthen have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z \u2227 HasMutation x z y\" sledgehammer', 'solving time': 103.38458609580994, 'proof tactics': [], 'code': 'theory clinical_96_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Common_BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  HasMutation :: \"entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. Patient x \u2227 Common_BRAF_V600E_Mutation y \u2227 HasMutation z x y \u27f6 (Receive e \u2227 Agent e x \u2227 Patient z \u2227 With x z)\"\\n\\n(* Explanation 2: If a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Patient y \u2227 With x z \u27f6 (Common_BRAF_V600E_Mutation z \u2227 HasMutation x z y)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient y \u2227 With x z\"\\nproof -\\n  (* From the premise, we know that the patient has a common BRAF V600E mutation and is receiving treatment with vemurafenib. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z\" <ATP>\\n  (* Using Explanation 2: If a patient is receiving treatment with vemurafenib, then the patient has a common BRAF V600E mutation. *)\\n  (* We can infer that the patient has a common BRAF V600E mutation and has a mutation related to the treatment. *)\\n  then have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z \u2227 HasMutation x z y\" <ATP>\\n  (* Using Explanation 1: If a patient has a common BRAF V600E mutation, then the patient is receiving treatment with vemurafenib. *)\\n  (* We can conclude that the patient is receiving treatment with vemurafenib. *)\\n  then have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Common_BRAF_V600E_Mutation z \u2227 Receive e \u2227 Agent e x \u2227 Patient y \u2227 With x z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a common BRAF V600E mutation\\nB: patient is receiving treatment with vemurafenib\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a common BRAF V600E mutation, patient is receiving treatment with vemurafenib)\\n--------\\nImplies(B, A)\\nImplies(patient is receiving treatment with vemurafenib, patient has a common BRAF V600E mutation)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}